Trava Health review

What it is

Trava Health is a Houston-based direct-to-consumer telehealth service co-founded by Charles Willis and Christopher Quintana, selling compounded medication across four categories: Weight Loss (compounded semaglutide and tirzepatide, each paired with B12), Anti-Aging & Wellness (NAD⁺ injection, NAD⁺ nasal spray, Lipo-B + B12, Lipo-C, vitamin B12, glutathione, metformin), Peptide Therapy (sermorelin) and Skincare (tretinoin). It discloses six 503A compounding pharmacy partners on its own legal pages — Postmeds/TruePill, EHT/Curexa, Apostrophe Pharmacy LLC, XeCare LLC, Wells American Inc dba Promed Pharmacy and Optimal Balance Pharmacy LLC dba OBP — and names Beluga Health and Bask Health as its clinical partners.

How it works

Quiz-led and asynchronous, with the consultation stated as included and no upfront payment required to begin. The disclosure posture is the reason to look at it. Naming one compounding pharmacy is unusual; naming six on your own Terms and Telehealth Consent pages, with legal entity names rather than trade names, is close to unique in our coverage, and it means the specific facility filling your order is at least drawn from a knowable set. Stating that batches are independently tested by Eagle Analytical, an FDA-registered lab, is a second real check. Set against that is a trust profile that has not caught up. No LegitScript badge is surfaced anywhere. Its own clinician roster page returns a 404, so the named clinical partnerships are not matched by named clinicians. No founder or CEO is identified on the site itself. And it carries an F rating with the Better Business Bureau tied to unanswered complaints, on a file opened in 2025, without accreditation. Which pharmacy fills a given order can vary, so if the source matters to you, ask before the first shipment rather than after.

Pricing transparency

Product-page pricing is per molecule, monthly, and states what is included — shipping and handling at no additional cost, shipped via FedEx — with a quarterly package offered as the only discount structure. Sermorelin is $157.91 a month at 3 mg, and because its homepage tile carries the identical figure, that is a price we can publish. NAD⁺ is where it breaks. The product page reads "$158.93 / monthly" for a 100 mg injection with a quarterly package saving $127.86; the homepage tile advertises the same product as "As Low As $127.86". Those cannot both be right, and the shape of the error is clear — the tile is displaying the quarterly saving in the price slot. We publish no NAD⁺ floor on that basis and quote the product-page figure with the contradiction attached. It is worth noting that the same tile pattern runs across the site, so check every headline against the product page before comparing anything: the record we hold also flags live GLP-1 figures ($88.65 semaglutide, $178.98 tirzepatide) that differ from the reference pricing on file. Higher-dose pricing on the GLP-1 side is gated behind the questionnaire rather than published.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Trava's six named 503A partners and its stated independent batch testing by Eagle Analytical put it ahead of most of this board on provenance, but compounded sterile products are still not reviewed by the FDA for purity and potency the way approved drugs are, and a compounded preparation of a molecule is not the trialled product. On evidence, the three items this board cares about sit at different tiers. Sermorelin is a GHRH analogue that stimulates your own pituitary rather than replacing growth hormone — a real, well-characterised mechanism whose long-term human outcome data stays thin beyond short-term IGF-1 movement, and Trava's 3 mg presentation is at least a specification you can compare. Injected and intranasal NAD⁺ have no controlled human outcome trials at all; the single human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears plasma quickly, and the forms with human trial data are the oral precursors NR and NMN, which raise a blood level rather than demonstrate an outcome. Injectable glutathione has essentially no controlled human outcome data behind the detoxification and skin claims attached to it. Individual results vary.

Pros and watch-outs

The evidence behind what Trava Health prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

• NAD injections: how to get them near you or online, and what the evidence really says

  Subcutaneous NAD+ injections are sold as a cheaper, at-home alternative to the IV drip — via “near me” clinics or telehealth shipped to your door. They’re compounded, not FDA-approved, and have no outcome trials; oral NR/NMN precursors are the route with the human data.

• NAD⁺ nasal spray: the delivery format with the least direct evidence

  Intranasal NAD⁺ is convenient and heavily marketed — but no controlled human trial shows the spray raises systemic or brain NAD⁺. A straight comparison with the better-studied routes.

• Glutathione: the master antioxidant, and where the evidence actually is

  Oral glutathione really does raise your body stores (a 6-month RCT proved it) — but the longevity and detox claims are unproven, skin-lightening is modest, and IV glutathione is the most marketed, least evidenced route. The precursors may be the smarter bet.

How Trava Health compares

A few alternatives worth a look, depending on what you’re optimizing for.

• TWTyde Wellness

  NAD⁺ buyers who want five named pharmacies, a published state list and the route stated with the price

  See Tyde Wellness →
• TETelePeptide

  NAD⁺ buyers who want the month-to-month rate published beside the prepay rates

  See TelePeptide →
• TRTrueMe

  Buyers in its six states who want the NAD⁺ price visible before handing over any health history

  See TrueMe →